A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant mel...

Date 28 September 2015
Event European Cancer Congress 2015
Session Melanoma and Skin Cancer II
Topics Melanoma and other Skin Tumours
Presenter van Herpen, C.